Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Revlimid® Capsules General Drug Use-results Survey (Relapsed or Refractory Follicular Lymphoma and Marginal Zone Lymphoma)

NCT04618081 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04618081
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04618081 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Revlimid® Capsules General Drug Use-results Survey (Relapsed or Refractory Follicular Lymphoma and Marginal Zone Lymphoma)
Lead sponsor
Celgene
Phase
Observational
Overall status
Completed
Start date
December 17, 2020
Completion date
March 27, 2025
Enrollment
151 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma nonhodgkin